DBV Technologies Share: 1.5% Rebound After Nearly 35% Decline in Three Months
The Châtillon biotech firm regains some ground at midday, in an SBF 120 oriented upward. This rebound comes after a long series of declines, while the file submitted to the FDA at the end of September has not altered the trajectory of the share price.
The DBV Technologies share gains 1.45% to €1.88, against €1.86 the previous day. This gain remains modest given the decline of 9.12% over one week and nearly 35% over three months. The price is trading below its 20-day moving average (€2.11, a gap of 10.76%), as well as below its 200-day moving average at €3.08, representing a gap of 38.86%.
It stands slightly above the €1.86 support level, which the share has been testing for several sessions. The RSI at 32 is close to the oversold zone, which alone does not indicate a reversal.
Short Positions Increasing Despite American Regulatory Progress
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
You're in — subscription confirmed!
Your first edition is on its way. Check your spam folder and add us to your contacts.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
Gratuit · chaque matin
Ne ratez plus rien sur vos actions
La tendance derrière les cours. L'essentiel des valeurs Euronext en quelques minutes.
📈les valeurs en mouvement, sur la durée
🎯les objectifs d'analystes qui évoluent
📰les actualités qui font bouger les cours
tendance · 6 séances
✓ C'est fait, vous êtes inscrit !
Votre première édition arrive bientôt. Pensez à vérifier vos spams.
Une erreur est survenue.
CAC 40 · SBF 120 · données indicatives · aucun conseil en investissement · désinscription à tout moment.
The submission of the biological license application to the FDA for the anti-peanut patch, announced on September 30, had triggered a rebound on the same day, which was erased the following day. According to the statements consulted, four funds hold 4.28% of capital in net short positions, compared to 3.64% thirty days ago, an increase of 0.64 percentage points. This rise shows that institutional investors remain positioned downward on the stock, without being able to infer their motivations.
When publishing the H1 2026 results on July 16, the company indicated sufficient cash until the third quarter of 2027, with no revenue at this stage. Its next regulatory milestone is the examination of its file by the FDA.
SectorPharmacie et biotechnologies›Biotechnologies
Free · every morning · before 9am
Never miss a move on your stocks
The trend behind the prices · Euronext
✓ You're in! Check your spam folder.
An error occurred.
Context
Period
Period: S1 2026
Key reported figures
Revenue: 1,6 millions de dollars
Quarterly revenue: 1,6 millions de dollars
Net income: -98 millions de dollars
Guidance from the release
DBV is a late-stage biopharmaceutical company currently in regulatory discussions with the FDA, with BLA submission anticipated in Q3 2026; the company reports cash funding into Q3 2027, indicating reliance on capital reserves and no current revenue generation.
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.
